Table 3.
Clinical characteristics related to FMT by tumor type
| Characteristic | Solid tumor group (n = 12) | Hematologic malignancy group (n = 7) |
|---|---|---|
| Endoscopic findings at time of FMT, no. (%) | ||
| Ulcers | 1 (8%) | 0 |
| Non-ulcer inflammation | 2 (17%) | 2 (29%) |
| Normal | 9 (75%) | 5 (71%) |
| Total number of FMT procedures a, no. | 14 | 7 |
| Complications related to FMT within 7 and 30 daysb, no. (%) | 2 (17%) | 1 (14%) |
| Median days from first FMT to diarrhea response or resolution, (IQR) (n = 11) | 1 (1-1.5) | 1.5 (1-2) |
| Non-remission after FMT, no. (%) | 4 (33%) | 1 (14%) |
| Median days from first FMT to first CDI recurrence, (IQR) (n = 5) | 212 (52-389) | NA |
| Non-CDI antibiotic use after FMT c, no. (%) | 7 (58%) | 3 (43%) |
| Use of immunosuppressant after FMT, no. (%) | 0 | 0 |
| Use of cancer chemotherapy after FMT, no. (%) | 1 (8%) | 0 |
| Mortality <30 days after FMT, no. (%) | 1 (8%) | 1 (14%) |
| Mortality related to FMT, no. (%) | 0 | 0 |
CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; IQR, interquartile range; NA, data is not available or could not be calculated.
a One case received a total of 3 FMT treatments.
b Only abdominal pain and nausea were reported as FMT-related new symptoms in 3 cases, with a duration of 1, 3 and 6 days.
cThe indications for antibiotic use after FMT include urinary tract infection, diverticulitis, cellulitis, otitis media, neutropenic fever, dental procedure.